Novo Nordisk Ramps Up Wegovy Production to Meet High Obesity Drug Demand
• Novo Nordisk forecasting double-digit growth in 2023, will expand Wegovy to new markets • Boosting US supplies of Wegovy starter doses by over 100% in January • Aiming to meet high demand and prevent losing market share to rivals like Lilly • Expect Wegovy prices to fall as production volumes increase and competition grows • News of improved Wegovy supplies seen as positive by investors